Piero Barbanti

List of Publications by Citations

117 papers	2,901 citations	30 h-index	48 g-index
129 ext. papers	3,495 ext. citations	5.2 avg, IF	5 L-index

#	Paper	IF	Citations
117	BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. *Cephalalgia*, **2011**, 31, 573-84	6.1	169
116	Unilateral cranial autonomic symptoms in migraine. *Cephalalgia*, **2002**, 22, 256-9	6.1	166
115	Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. *Neurological Sciences*, **2002**, 23, 41-3	3.5	133
114	Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. *Neurology*, **2018**, 91, e364-e373	6.5	130
113	A mechanism-based classification of pain in multiple sclerosis. *Journal of Neurology*, **2013**, 260, 351-67	5.5	118
112	Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study. *Journal of Headache and Pain*, **2015**, 16, 61	8.8	94
111	Excessive daytime sleepiness in de novo and treated Parkinson's disease. *Movement Disorders*, **2002**, 17, 1026-30	7	78
110	Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. *Movement Disorders*, **1999**, 14, 764-71	7	76
109	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. *Journal of Headache and Pain*, **2019**, 20, 92	8.8	65
108	Donepezil in the treatment of progressive supranuclear palsy. *Acta Neurologica Scandinavica*, **2001**, 103, 123-5	3.8	60
107	Migraine patients show an increased density of dopamine D3 and D4 receptors on lymphocytes. *Cephalalgia*, **2000**, 20, 15-9	6.1	57
106	Dopamine hypersensitivity in migraine: role of the apomorphine test. *Clinical Neuropharmacology*, **1997**, 20, 36-41	1.4	54
105	A case-control study on excessive daytime sleepiness in episodic migraine. *Cephalalgia*, **2007**, 27, 1115-96.1	6.1	53
104	Polymorphism at codon 129 or codon 219 of PRNP and clinical heterogeneity in a previously unreported family with Gerstmann-Str□ssler-Scheinker disease (PrP-P102L mutation). *Neurology*, **1996**, 47, 734-41	6.5	52
103	Reduced density of dopamine D2-like receptors on peripheral blood lymphocytes in Alzheimer's disease. *Mechanisms of Ageing and Development*, **2000**, 120, 65-75	5.6	52
102	Prevalence and Time Course of Post-Stroke Pain: A Multicenter Prospective Hospital-Based Study. *Pain Medicine*, **2016**, 17, 924-30	2.8	49
101	The phenotype of migraine with unilateral cranial autonomic symptoms documents increased peripheral and central trigeminal sensitization. A case series of 757 patients. *Cephalalgia*, **2016**, 36, 1334-1340	6.1	44

100	A meta-analysis of biomarkers related to oxidative stress and nitric oxide pathway in migraine. *Cephalalgia*, **2015**, 35, 931-7	6.1	43
99	Increased density of dopamine D5 receptor in peripheral blood lymphocytes of migraineurs: a marker for migraine?. *Neuroscience Letters*, **1996**, 207, 73-6	3.3	43
98	Dopaminergic symptoms in migraine. *Neurological Sciences*, **2013**, 34 Suppl 1, S67-70	3.5	42
97	Amitriptyline is effective in chronic but not in episodic tension-type headache: pathogenetic implications. *Headache*, **1998**, 38, 453-7	4.2	42
96	Hypertension as a risk factor for migraine chronification. *Neurological Sciences*, **2010**, 31 Suppl 1, S41-3	3.5	41
95	Differences in short-term primary motor cortex synaptic potentiation as assessed by repetitive transcranial magnetic stimulation in migraine patients with and without aura. *Pain*, **2010**, 148, 43-48	8	41
94	Shortened cortical silent period in facial muscles of patients with migraine. *Pain*, **2007**, 132, 124-31	8	40
93	Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study. *Journal of Headache and Pain*, **2016**, 17, 91	8.8	39
92	Dopamine and migraine: does Parkinson's disease modify migraine course?. *Cephalalgia*, **2000**, 20, 720-3	6.1	38
91	Prolonged muscular flaccidity after stroke. Morphological and functional brain alterations. *Brain*, **1995**, 118 (Pt 5), 1329-38	11.2	36
90	Sumatriptan in migraine with unilateral cranial autonomic symptoms: an open study. *Headache*, **2003**, 43, 400-3	4.2	34
89	Ketogenic diet in migraine: rationale, findings and perspectives. *Neurological Sciences*, **2017**, 38, 111-115	3.5	33
88	Erenumab: from scientific evidence to clinical practice-the first Italian real-life data. *Neurological Sciences*, **2019**, 40, 177-179	3.5	30
87	Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial. *Journal of Headache and Pain*, **2012**, 13, 407-14	8.8	27
86	Drugs targeting nitric oxide synthase for migraine treatment. *Expert Opinion on Investigational Drugs*, **2014**, 23, 1141-8	5.9	25
85	A case-control study on excessive daytime sleepiness in chronic migraine. *Sleep Medicine*, **2013**, 14, 278-84	4.6	25
84	Erenumab in the prevention of high-frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real-life study. *Headache*, **2021**, 61, 363-372	4.2	25
83	Cerebral transverse sinus morphology as detected by MR venography in patients with chronic migraine. *Headache*, **2012**, 52, 1254-61	4.2	24

82	Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). *Journal of Headache and Pain*, **2021**, 22, 35	8.8	24
81	Late motor recovery is influenced by muscle tone changes after stroke. *Archives of Physical Medicine and Rehabilitation*, **2005**, 86, 308-11	2.8	23
80	Excessive daytime somnolence in Parkinson's disease. Follow-up after 1 year of treatment. *Neurological Sciences*, **2003**, 24, 178-9	3.5	23
79	A systems medicine clinical platform for understanding and managing non- communicable diseases. *Current Pharmaceutical Design*, **2014**, 20, 5945-56	3.3	23
78	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. *Journal of Headache and Pain*, **2018**, 19, 101	8.8	23
77	Restless legs syndrome is not associated with migraine with aura: a clinical study. *Neurological Sciences*, **2011**, 32 Suppl 1, S153-6	3.5	22
76	Non-invasive vagus nerve stimulation (nVNS) as symptomatic treatment of migraine in young patients: a preliminary safety study. *Neurological Sciences*, **2017**, 38, 197-199	3.5	21
75	Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations. *Journal of Pain Research*, **2017**, 10, 2319-2329	2.9	21
74	Pharmacological trials in migraine: it's time to reappraise where the headache is and what the pain is like. *Headache*, **2015**, 55, 439-41	4.2	21
73	Comparison of frovatriptan plus dexketoprofen (25 mg or 37.5 mg) with frovatriptan alone in the treatment of migraine attacks with or without aura: a randomized study. *Cephalalgia*, **2014**, 34, 434-45	6.1	21
72	Migraine and the extrapyramidal system. *Cephalalgia*, **2002**, 22, 2-11	6.1	21
71	Headache in cranial and cervical dystonia. *Neurology*, **2005**, 64, 1308-9	6.5	21
70	Redox Mechanisms in Migraine: Novel Therapeutics and Dietary Interventions. *Antioxidants and Redox Signaling*, **2018**, 28, 1144-1183	8.4	20
69	The role of anti-CGRP antibodies in the pathophysiology of primary headaches. *Neurological Sciences*, **2017**, 38, 31-35	3.5	19
68	Migraine prophylaxis: what is new and what we need?. *Neurological Sciences*, **2011**, 32 Suppl 1, S111-5	3.5	18
67	Prolonged muscular flaccidity: frequency and association with unilateral spatial neglect after stroke. *Acta Neurologica Scandinavica*, **1993**, 88, 313-5	3.8	18
66	Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine. *Neurological Sciences*, **2015** , 36 Suppl 1, 29-32	3.5	16
65	Is SOD2 Ala16Val polymorphism associated with migraine with aura phenotype?. *Antioxidants and Redox Signaling*, **2015**, 22, 275-9	8.4	16

64	Validation of a self-reported instrument to assess work-related difficulties in patients with migraine: the HEADWORK questionnaire. *Journal of Headache and Pain*, **2018**, 19, 85	8.8	16
63	Circulating Biomarkers in Migraine: New Opportunities for Precision Medicine. *Current Medicinal Chemistry*, **2019**, 26, 6191-6206	4.3	15
62	Dopaminergic symptoms in migraine: A cross-sectional study on 1148 consecutive headache center-based patients. *Cephalalgia*, **2020**, 40, 1168-1176	6.1	14
61	Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. *Headache*, **2021**, 61, 1351-1363	4.2	14
60	Serotonin receptor targeted therapy for migraine treatment: an overview of drugs in phase I and II clinical development. *Expert Opinion on Investigational Drugs*, **2017**, 26, 269-277	5.9	13
59	Establishment of a biorepository for migraine research: the experience of Interinstitutional Multidisciplinary BioBank (BioBIM). *Neurological Sciences*, **2013**, 34, 1659-63	3.5	13
58	Migraine and movement disorders. *Neurological Sciences*, **2012**, 33 Suppl 1, S55-9	3.5	13
57	Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. *Current Medical Research and Opinion*, **2004**, 20, 2021-9	2.5	13
56	Look beyond Catechol-O-Methyltransferase genotype for cathecolamines derangement in migraine: the BioBIM rs4818 and rs4680 polymorphisms study. *Journal of Headache and Pain*, **2015**, 16, 520	8.8	12
55	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. *Journal of Headache and Pain*, **2018**, 19, 98	8.8	12
54	Socio-economic costs of migraine. *Journal of Headache and Pain*, **2001**, 2, s15-s19	8.8	11
53	Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial. *Cephalalgia*, **2015**, 35, 45-50	6.1	10
52	Trigeminal sensory pathway function in patients with SUNCT. *Clinical Neurophysiology*, **2006**, 117, 1821-5	4.3	10
51	Migraine and Tourette syndrome. *Archives of Neurology*, **2004**, 61, 606-7; author reply 607		10
50	Migraine as a Cortical Brain Disorder. *Headache*, **2020**, 60, 2103-2114	4.2	10
49	No association between essential tremor and migraine: a case-control study. *Cephalalgia*, **2010**, 30, 686-9	6.1	9
48	Acute pathological laughter induced by sumatriptan. *Cephalalgia*, **2008**, 28, 92-3	6.1	9
47	Impact of the International Headache Society criteria on the use of neuroimaging for headache diagnosis in a headache clinic. *Headache*, **1999**, 39, 747-51	4.2	9

46	Prolonged Muscular Flaccidity in Stroke Patients Is Associated with Crossed Cerebellar Diaschisis. *Cerebrovascular Diseases*, **1993**, 3, 80-85	3.2	9
45	Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study). *Neurological Sciences*, **2020**, 41, 487-488	3.5	9
44	Pharmacotherapy for acute migraines in children and adolescents. *Expert Opinion on Pharmacotherapy*, **2019**, 20, 455-463	4	9
43	Acupuncture in cluster headache: four cases and review of the literature. *Neurological Sciences*, **2014**, 35 Suppl 1, 195-8	3.5	8
42	Efficacy of frovatriptan and other triptans in the treatment of acute migraine of hypertensive and normotensive subjects: a review of randomized studies. *Neurological Sciences*, **2013**, 34 Suppl 1, S87-91	3.5	8
41	Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study. *Neurological Sciences*, **2020**, 41, 3385-3389	3.5	8
40	Dopamine-beta-hydroxylase 19-bp insertion/deletion polymorphism affects medication overuse in patients with chronic migraine. *Neurological Sciences*, **2019**, 40, 1717-1724	3.5	7
39	Real-world insights on the management of migraine patients: an Italian nationwide study. *Current Medical Research and Opinion*, **2019**, 35, 1545-1554	2.5	7
38	Treatment of tension-type headache: from old myths to modern concepts. *Neurological Sciences*, **2014**, 35 Suppl 1, 17-21	3.5	7
37	Headache in chronic cocaine users: A cross-sectional study. *Cephalalgia*, **2014**, 34, 671-678	6.1	7
36	Association between migraine and ACE gene (insertion/deletion) polymorphism: the BioBIM study. *Pharmacogenomics*, **2014**, 15, 147-55	2.6	7
35	Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study).. *Journal of Headache and Pain*, **2022**, 23, 46	8.8	7
34	Does the migraine attack start in the cortex and is the cortex critical in the migraine process?. *Neurological Sciences*, **2019**, 40, 31-37	3.5	6
33	Progesterone receptor gene (PROGINS) polymorphism correlates with late onset of migraine. *DNA and Cell Biology*, **2015**, 34, 208-12	3.6	6
32	Machine learning approach to predict medication overuse in migraine patients. *Computational and Structural Biotechnology Journal*, **2020**, 18, 1487-1496	6.8	6
31	Trigeminal-Targeted Treatments in Migraine: Is 60% the Magic Number?. *Headache*, **2019**, 59, 1659-1661	4.2	6
30	Prion protein gene M129V polymorphism and variability in age at migraine onset. *Headache*, **2013**, 53, 540-5	4.2	6
29	Tardive dyskinesias in the elderly. *International Journal of Geriatric Psychiatry*, **2001**, 16 Suppl 1, S19-23	3.9	6

28	Tension type headache: a neuropsychological and neurophysiological study. *Italian Journal of Neurological Sciences*, **1992**, 13, 331-6		6
27	Applications of Ketogenic Diets in Patients with Headache: Clinical Recommendations. *Nutrients*, **2021**, 13,	6.7	6
26	Establishment of an Italian chronic migraine database: a multicenter pilot study. *Neurological Sciences*, **2018**, 39, 933-937	3.5	5
25	Procoagulant imbalance in premenopausal women with chronic migraine. *Neurology*, **2017**, 89, 1525-1527	6.5	5
24	When should we consider chronic patients as non-responders to monoclonal antibodies targeting the CGRP pathway?. *Journal of Neurology*, **2021**, 1	5.5	5
23	Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study.. *Journal of Headache and Pain*, **2021**, 22, 154	8.8	5
22	HEADWORK Questionnaire: Why Do We Need a New Tool to Assess Work-Related Disability in Patients With Migraine?. *Headache*, **2020**, 60, 497-504	4.2	4
21	Efficacy of early vs. late use of frovatriptan combined with dexketoprofen vs. frovatriptan alone in the acute treatment of migraine attacks with or without aura. *Neurological Sciences*, **2014**, 35 Suppl 1, 107-13	3.5	4
20	Dopamine and migraine. *Neurology*, **1998**, 51, 925	6.5	4
19	Rapid response to galcanezumab and predictive factors in chronic migraine patients: A 3-month observational, longitudinal, cohort, multicenter, Italian real-life study. *European Journal of Neurology*, **2021**,	6	4
18	The evaluation of difficulties with work-related activities caused by migraine: towards a specific questionnaire. *Neurological Sciences*, **2018**, 39, 131-133	3.5	3
17	Sumatriptan fast-disintegrating/rapid-release tablets in the acute treatment of migraine. *Expert Review of Neurotherapeutics*, **2007**, 7, 927-34	4.3	3
16	Clinical features, disease progression, and use of healthcare resources in a large sample of 866 patients from 24 headache centers: A real-life perspective from the Italian chROnic migraiNe (IRON) project. *Headache*, **2021**, 61, 936-950	4.2	3
15	Early (≤1-h) vs. late (>1-h) administration of frovatriptan plus dexketoprofen combination vs. frovatriptan monotherapy in the acute treatment of migraine attacks with or without aura: a post hoc analysis of a double-blind, randomized, parallel group study. *Neurological Sciences*, **2015**, 36 Suppl 1, 161-7	3.5	2
14	Future trends in drugs for migraine prophylaxis. *Neurological Sciences*, **2012**, 33 Suppl 1, S137-40	3.5	2
13	Erenumab during pregnancy: a case report in a patient with chronic migraine. *Neurological Sciences*, **2021**, 42, 2145-2146	3.5	2
12	Predictors of response to onabotulinumtoxin A in chronic migraine. *European Journal of Neurology*, **2018**, 25, e40	6	1
11	Chronic migraine: treatability, refractoriness, pseudo-refractoriness. *Journal of Headache and Pain*, **2015**, 16, A39	8.8	1

10	O036. Cocaine and headache: a 2-year follow-up study in chronic cocaine users and literature review. *Journal of Headache and Pain*, **2015**, 16, A167	8.8	1
9	A proposal for a national registry on chronic migraines. *Journal of Headache and Pain*, **2015**, 16, A40	8.8	1
8	Cluster headache: management of acute attacks before triptans. *Italian Journal of Neurological Sciences*, **1999**, 20, S63-5		1
7	Genetic bases of the nutritional approach to migraine. *Critical Reviews in Food Science and Nutrition*, **2019**, 59, 2308-2320	11.5	1
6	Gender Differences in 3-Month Outcomes of Erenumab Treatment-Study on Efficacy and Safety of Treatment With Erenumab in Men.. *Frontiers in Neurology*, **2021**, 12, 774341	4.1	1
5	Dopamine and Migraine: Does Parkinson's Disease Modify Migraine Course?		0
4	Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.. *Journal of Headache and Pain*, **2022**, 23, 38	8.8	0
3	Headache in Cocaine Users: Epidemiology, Clinical Features, and Putative Pathophysiological Mechanisms **2017**, 363-374		
2	O039. Case-control genetic association studies in migraine: a 7-year experience at the Interinstitutional Multidisciplinary Biobank (BioBIM) of IRCCS San Raffaele Pisana. *Journal of Headache and Pain*, **2015**, 16, A120	8.8	
1	Impairment of trigeminal sensory pathways in cluster headache. *Cephalalgia*, **2004**, 24, 910; author reply 910-1	6.1	